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Relaxin-3 is a highly conserved neuropeptide in vertebrate species and binds to the Class
A G protein-coupled receptor (GPCR) RXFP3. Relaxin-3 is involved in a wide range of
behaviors, including feeding, stress responses, arousal, and cognitive processes and
therefore targeting of RXFP3 may be relevant for a range of neurological diseases.
Structural knowledge of RXFP3 and its interaction with relaxin-3 would both increase our
understanding of ligand recognition in GPCRs that respond to protein ligands and enable
acceleration of the design of drug leads. In this study we have used comparative sequence
analysis, molecular modeling and receptor mutagenesis to investigate the binding site of
the native ligand human relaxin-3 (H3 relaxin) on the human RXFP3 receptor. Previous
structure function studies have demonstrated that arginine residues in the H3 relaxin
B-chain are critical for binding interactions with the receptor extracellular loops and/or
N-terminal domain. Hence we have concentrated on determining the ligand interacting
sites in these domains and have focused on glutamic (E) and aspartic acid (D) residues in
these regions that may form electrostatic interactions with these critical arginine residues.
Conserved D/E residues identiﬁed from vertebrate species multiple sequence alignments
were mutated to Ala in human RXFP3 to test the effect of loss of amino acid side chain
on receptor binding using a Eu-labeled relaxin-3 agonist. Finally data from mutagenesis
experiments have been used in ligand docking simulations to a homology model of human
RXFP3 based on the peptide-bound chemokine receptor 4 (CXCR4) structure.These studies
have resulted in a model of the relaxin-3 interaction with RXFP3 which will inform further
interrogation of the agonist binding site.
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INTRODUCTION
Relaxin-3 is a member of the relaxin peptide family. Peptides from
this family activate relaxin family peptide (RXFP) receptors, which
are Type I or Class A G protein-coupled receptors (GPCRs). It is
now well-established that RXFP3 [also called somatostatin- and
angiotensin-like peptide receptor (SALPR) or GPCR135] is the
endogenous receptor for relaxin-3 (Liu et al., 2003b), although
relaxin-3 is also able to bind to and activate both RXFP4 (Liu
et al., 2003a) and RXFP1 (Sudo et al., 2003), the receptors of the
related insulin-like peptide-5 (INSL5) and relaxin-2, respectively.
The relaxin-3 gene is the ancestral gene of the relaxin peptide fam-
ily (Bathgate et al., 2002) and highly homologous relaxin-3 genes
are found in ﬁsh, chicken, and frog genomes (Wilkinson et al.,
2005b). Relaxin-3 is found in a few discrete nuclei in the brain-
stem of macaque monkeys (Ma et al., 2009b), rodents (Bathgate
et al., 2002; Burazin et al., 2002), and zebraﬁsh (Donizetti et al.,
2008) with the most prominent expression in the “nucleus incer-
tus” (NI; Tanaka et al., 2005). This lies in the dorsomedial pons,
adjacent to other nuclei involved in neurohumoral responses to
stress (Ma et al., 2007). Relaxin-3 neurons project to a number
of brain regions where the peptide is localized in presynaptic
vesicles of nerve terminals innervating a range of areas containing
RXFP3-positive neurons (Ma et al., 2007). These innervated areas
are involved in regulating behaviors such as sleep/wakefulness,
arousal/attention and mood, stress responses and associated cog-
nitive processes, the activity of which is perturbed in a range of
psychiatric diseases and in animal models of these disorders (Ma
et al., 2007).
Relaxin-3 is involved in a wide range of behaviors, includ-
ing feeding, stress responses, arousal, and cognitive processes
(Smith et al., 2011). Central administration of relaxin-3 has been
shown to increase feeding in rats (McGowan et al., 2005, 2006;
Ganella et al., 2012b). A more recent study has demonstrated that
chronic viral mediated delivery of a relaxin-3 peptide agonist in
the hypothalamus chronically increases feeding andbodyweight in
rats by a novel mechanism that does not make the animals obese
(Ganella et al., 2012a). Relaxin-3 neuronal activity and produc-
tion of relaxin-3 mRNA is increased by stress (Tanaka et al., 2005).
RXFP3 antagonist injection into the medial septum inhibits spa-
tial memory in rats, indicating a role for relaxin-3 in cognition
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(Ma et al., 2009a). Hence targeting of RXFP3 may be relevant for
a range of neurological diseases.
The relaxin ligands are complex molecules that are struc-
turally related to insulin comprising two-peptide chains (A- and
B-chain) that are cross-braced by three disulﬁde bonds (Bathgate
et al., 2006). The nuclear magnetic resonance solution structure
of human relaxin-3 (H3 relaxin) has revealed that the 24 residue
A-chain forms two helical segments arranged in an antiparallel
fashion, with the 27 residue B-chain adopting a third helix that
lies perpendicular to the A-chain helices (Rosengren et al., 2006).
Importantly, while features of both the relaxin-3 A- and B-chain
are required for binding to RXFP1 (Haugaard-Jonsson et al., 2008;
Hossain et al., 2008), the B-chain alone is responsible for inter-
acting with RXFP3 and RXFP4 (Kuei et al., 2007; Hossain et al.,
2008; Haugaard-Kedstrom et al., 2011). The A-chain likely pro-
vides a scaffold that supports the correct structure of the B-chain
(Hossain et al., 2008). Studies using H3 relaxin peptide mutants
have demonstrated that residues around the B-chain central helix
including R8, R12, I15, R16, and F20 are important for RXFP3
bindingwhereas all except R12 are also important for RXFP4 bind-
ing (Kuei et al., 2007; Figure 1B). Additionally, the C-terminal two
residues of the B-chain R26 and W27 were demonstrated to be
essential for receptor activation (Kuei et al., 2007; Figure 1B). It
is likely that the residues from the central helix are involved with
interactions with the extracellular domains of the receptors while
R26 and W27 may interact within the RXFP3 transmembrane
helices (Kuei et al., 2007; Kong et al., 2010).
Although residues in the peptides have been identiﬁed as critical
for activity, the speciﬁc residues in the receptors that are interacting
with these are unknown. A recent study utilized the selectivity of
INSL5 for RXFP4 over RXFP3 and characterized the ligand inter-
actions of chimeric RXFP3/4 receptors in order to identify the
N-terminus (NT) and transmembrane exoloop 2 (EL2) of RXFP4
as the sites of INSL5binding. In addition they determined that sites
FIGURE 1 | (A) Sequence alignment using Boxshade of representative
mammalian (human, chimpanzee, rat, mouse, platypus) and representative
lower vertebrate RXFP3 sequences (Frog and Zebraﬁsh) compared
to human RXFP4. Only residues from the extracellular N-terminus and
extracellular loops (ELs) are shown and the N-terminus is aligned from
amino acid 34 of human RXFP3. All the glutamic (E) and aspartic acid
(D) residues in the extracellular domain are highlighted with those
conserved in RXFP3 and RXFP4 in yellow and those conserved in
RXFP3 only in red. Conserved potential N-glycosylation sites are
highlighted in green. Highly conserved amino acids across all
species are boxed in black and conservative amino acid substitutions
are boxed and shaded. (B) Human relaxin-3 peptide sequence with
the key B-chain residues involved in receptor binding and activation
highlighted.
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in transmembrane (TM) 2, 3, and 5 are involved in receptor acti-
vation by INSL5 (Zhu et al., 2008). None of the receptor chimeras
resulted in appreciable changes in relaxin-3 binding or activity
highlighting that relaxin-3 binds to and activates RXFP4 in a simi-
larmanner toRXFP3. In this studywe have utilized comprehensive
sequence analysis of RXFP3 and RXFP4 from multiple vertebrate
species to predict interacting residues, focusing on Asp and Glu
residues as likely partners for the three key Arg residues in H3
relaxin, and analyzed the effect of mutation of these residues using
binding studies. Finally ligand docking and molecular modeling
was used to determine potential sites of interaction of relaxin-3
with the RXFP3 receptor.
MATERIALS AND METHODS
REAGENTS
Synthetic H3 relaxin was chemically prepared as previously
described (Bathgate et al., 2006). The mono-Eu-labeled relaxin-
3 agonist H3 relaxin B-chain, INSL5 A chain (H3/I5) which
maintained high afﬁnity for receptor binding studies, has been
described previously (Luo et al., 2010). All synthetic oligonu-
cleotides were purchased from Sigma Aldrich and are listed in
Tables 1 and 2. PCR reactions and cloning were undertaken as
previously described (Scott et al., 2006, 2012).
RXFP3 SEQUENCE ANALYSIS
To highlight potential ligand interacting residues in the RXFP3
extracellular domains, we performed multiple sequence align-
ments of all the RXFP3/4 sequences identiﬁed from mammalian
genomes together with RXFP3/4 sequences from lower vertebrate
genomes (Wilkinson et al., 2005a; Wilkinson and Bathgate, 2007).
Sequences were retrieved from available genomes at Ensembl
(http://www.ensembl.org) and NCBI and aligned using ClustalW
with default parameters and shaded using Boxshade.
MAMMALIAN EXPRESSION CONSTRUCTS
A pcDNA3.1zeo (+) vector with a start codon and HA tag
(pcDNA3.1zeo (+)-HA) was produced by ligating a double
stranded primer containing a BamHI site at the 5′ end followed by
a start codon and HA tag and then a EcoRV blunt site at the 3′ end
(Table 2) into a pcDNA3.1zeo (+) vector cut with BamHI and
EcoRV. The 1XHA-tagged human RXFP3 vector (pcDNA3.1zeo
(+)-HA-RXFP3) was produced by ligating a polymerase chain
reaction (PCR) generated RXFP3 construct missing the ATG start
codon and with a EcoRV site at the 5′ end and a XhoI site at the
3′ end following the TGA stop site (primers listed in Table 2)
into the pcDNA3.1zeo (+)-HA construct. The DNA template
of N-terminal truncated mutant (HA-RXFP3 Δ1–33) was pre-
pared by PCR ampliﬁcation from pcDNA3.1zeo (+)-HA-RXFP3
using forward and reverse primers containing EcoRV and XhoI
sites, respectively (listed in Table 1). This product was ligated
in the pcDNA3.1zeo (+)-HA construct to create pcDNA3.1zeo
(+)-HA-RXFP3 Δ1–33. Final constructs were conﬁrmed by DNA
sequencing on both strandswhile at the same time conﬁrming that
there were no additional unwanted mutations in the sequence of
the receptor.
SITE DIRECTED MUTAGENESIS
The same protocol was used to prepare DNA templates of all
Glu/Asp to Ala mutants, entailing a single codon change except
for D47A/E51A, E55A/D58A, and E141A/D145Awhich required a
double codon change both toAla. The forward and reverse primers
for all mutants are listed in Table 1 and mutagenesis reactions
on pcDNA3.1zeo (+)-HA-RXFP3 were performed as previously
described (Scott et al., 2006; Yan et al., 2008). Individual clones
were screened, and the identities of individualmutationswere con-
ﬁrmed byDNA sequencing on both strands while at the same time
conﬁrming that there were no additional unwanted mutations in
the full length sequence of the receptor.
LIGAND BINDING AND CELL SURFACE EXPRESSION ASSAYS
HEK-293T cells were transfected in 96 well optiplates (Perkin
Elmer) with plasmids encoding the constructs of interest and
Eu-H3/I5 binding assays conducted as described previously (Luo
et al., 2010; Haugaard-Kedstrom et al., 2011). Speciﬁc binding
assays were conducted using 5 nM Eu-H3/I5 in the absence (total
binding) or presence (non-speciﬁc binding) of 1 μM unlabeled
H3 relaxin to determine speciﬁc binding (total binding − non-
speciﬁc binding). Competition binding assays were performed as
above with increasing concentrations of unlabeled H3 relaxin and
non-speciﬁc binding was determined using 1 μM unlabeled H3
relaxin. Binding data are expressed as mean ± standard error of
mean (SEM) of % speciﬁc binding of triplicate measurements
pooled from at least three independent experiments. Data were
analyzed using Graphpad PRISM (Graphpad Inc.) and a non-
linear regression one-site binding model was used to plot curves
and calculate pIC50 values. All the RXFP3 constructs used in this
study contained an N-terminal HA epitope. The HA epitope was
detected using a puriﬁed mouse monoclonal anti-HA antibody
[HA.11(16B12), Covance] and a Alexaﬂuor488-labeled goat anti
mouse IgG (Invitrogen) in cell surface expression assays that were
Table 1 | Primers for the production of pcDNA3.1 (+)-HA, pcDNA3.1 (+)-HA-RXFP3, and pcDNA3.1 (+)-HA-RXFP3 Δ1–33 constructs.
Construct Primer name Sequence (5′–3′)
pcDNA3.1 (+)-HA HATag Fwd GAT CCG CCA CCATGT ACC CAT ACG ATGTTC CAG ATT ACG CTG AT
HATag Rev ATC AGC GTA ATCTGG AAC ATC GTATGG GTA CAT GGT GGC G
pcDNA3.1 (+)-RXFP3-HA RXFP3-HA EcoRV (no ATG) Fwd GAG AGG ATATCC AGATGG CCG ATG CAG CCA C
RXFP3-HA Rev GAG AGCTCG AGT CAGTAG GCA GAG CTG CTG G
pcDNA3.1(+)-RXFP3-HA Δ1–33 EcoRV Fwd GAGAG GAT ATC GCG GCC AAC ACG AGT GG
pcDNAMCS Rev CAA CAG ATG GCT GGC AACTA
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Table 2 | Site-directed mutagenesis primers for HA-RXFP3 D/E to A
mutants.
Mutation Direction Primer sequence (5′–3′)
E47A/D51A Fwd CCG GCCTTGTGGTGG GCG CTG GGG C
Rev CAG CGC CCA CCA CAA GCC CGG AAG CTG
E55A/D58A Fwd CTG GCCTTG CCG GCC GGC GCG CCG CC
Rev GCC GGC CGG CAA GGC CAG CCC CAG CTC
CCA CC
E72A Fwd GCA GCG AGC GCG GAC ACA GAG GCC C
Rev GCT CGCTGC CCC GCC GCT G
D75A Fwd GCG GCC ACA GAG GCC CGG GTG C
Rev CTGT GGC CGC GCT CTCTGC CCC
E77A Fwd CACA GCG GCC CGG GTG CGG ATT CTC ATC
Rev GGC CGCTGT GTC CGC GCT CTCTGC CC
E141A/D145A Fwd GTGGCCAACGCTCTTGCCTTCAAATGGCCC
TTC GGC AAG G
Rev GAA GGC AAG AGC GTT GGC CAC CGC CCA
GAA GGG CAG
E141A Fwd GTG GCC AAC GCT CTT GACTTC AAATGG
CCCTTC
Rev GTT GGC CAC CGC CCA GAA GGG CAG
D145A Fwd CTTGCCTTCAAATGGCCCTTCGGCAAGGCC
Rev GAA GGC AAG AGC GTT CTC CAC CGC CCA G
E244A Fwd GGC GCC GAG CTGTGC CTG GTG CGTTTC
Rev CTC GGC GCC CAT CAC CTT GAC CGT GG
E245A Fwd GAG GCC CTGTGC CTG GTG CGTTTC C
Rev CAG GGC CTC GCC CAT CAC CTT GAC CG
E253A Fwd CCG GCC AAGTTG CTG GGC CGC G
Rev CTT GGC CGG GAA ACG CAC CAG GC
D259A Fwd CGC GCC AGG CAGTTCTGG CTG GGC CTC
Rev CCT GGC GCG GCC CAG CAA CTT GTC CG
E362A Fwd CAG GCG ATT TTCC TGT GCC AGG TAT ACG
CGTTC
Rev GAA ATA CGC CTG GCT GAA GGG CAC CGC G
performed in 24 well plates as previously described (Yan et al.,
2008). Cell surface expression was determined by subtracting
the non-speciﬁc binding in pcDNA3.1 control transfected cells
and then dividing by the HA-RXFP3 expression to give %HA-
RXFP3 expression. Speciﬁc binding data for RXFP3 mutants was
expressed as mean± SEM of % speciﬁc binding/%HA-RXFP3 cell
surface expression of triplicate measurements pooled from at least
three independent experiments. Pooled data were analyzed using
one-wayANOVAcoupled toNewman–Keulsmultiple comparison
test for multiple group comparison.
MOLECULAR MODELING
A model of RXFP3 in complex with H3 relaxin was created
using the NMR solution structure of H3 relaxin (PDB identi-
ﬁer 2fhw) (Rosengren et al., 2006) and the crystal structure of
the chemokine receptor CXCR4 in complex with the antagonist
CVX15 (PDB identiﬁer 3oe0; Wu et al., 2010). An alignment
between the sequences of the two receptors was initially created
using Muscle (Edgar, 2004). CXCR4 shares 30% identity and 60%
similarity with RXFP3. RXFP3 has 80 additional residues at the
N-terminus compared to the crystal structure of CXCR4, and
this part of the protein has no homologous structure in the PDB.
Consequently, the ﬁrst 50 residues of RXFP3 were not modeled,
whereas the remaining part of the N-terminus, which has been
shown to have some inﬂuence on the activity, was modeled as
disordered. Extracellular loops 1 and 2 comprise two and seven
additional residues, respectively, in RXFP3 compared to CXCR4.
The additional residues were inserted at positions 101–102 and
192–193 (CXCR4 numbering). A model of RXFP3 was build by
comparison using Modeller 9v10 (Sali and Blundell, 1993), and
the two loops that are longer in RXFP3 were further reﬁned
within Modeller (Fiser et al., 2000). H3 relaxin was docked into
the receptor during the comparative modeling procedure using
the similarity of sequence between the N-terminus of CVX15 and
of the C-terminus of the H3 relaxin chain B, as well as by intro-
ducing loose distance restraints between the negatively charged
patch on the surface of RXFP3 that was shown to be important
for binding (D145 and E244) and the positively charged residues
R12 and R16 of the H3 relaxin B-chain. The two residues R2
and naphthalene-2-yl-3-alanine at position 3 of CVX15 deeply
dive into the binding site in between the transmembrane helices
of CXCR4, and their physico–chemical similarities with the B-
chain residues R26 and W27, which are vital for activity of H3
relaxin, were used to introduce positional restraints between H3
relaxin and RXFP3. 100 models were generated using Modeller
and the model with the lowest discrete optimized protein energy
(DOPE) scope (Shen and Sali, 2006) was selected as the most
representative.
RESULTS
SEQUENCE ALIGNMENTS
Based on the hypothesis that coevolution of relaxin-3 and RXFP3
occurred in vertebrates and that residues important for relaxin-3
binding and activation should therefore be conserved we per-
formed multiple sequence alignments of all vertebrate RXFP3
sequences. As H3 relaxin also binds to and activates human
RXFP4 (Liu et al., 2003a) we have also used human RXFP4 in
the sequence analysis. Figure 1A highlights sequence alignments
of representative mammalian species (human, chimpanzee, rat,
mouse, platypus) and representative lower vertebrate species (Frog
and Zebraﬁsh) from this analysis compared to human RXFP4.We
have concentrated on the extracellular domains of the receptor as
residues in the N-terminus and ELs are likely interacting with the
key binding residues in the central helix of the relaxin-3 B-chain
(Figure 1B). Additionally, we have focused on glutamic (E) and
aspartic acid (D) residues in these regions that may form electro-
static interactions with critical arginine residues in the relaxin-3
B-chain. As R12 has been demonstrated to not be involved in
RXFP4 binding whereas R8 and R16 have (Kuei et al., 2007), we
have highlighted residues conserved in only RXFP3 sequences in
red and those conserved in RXFP3 and RXFP4 in yellow. All of
these identiﬁed E/D residues are highlighted in more detail in
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Figure 2 which also demonstrates where we have truncated the N-
terminus to residue 34 to produce the mutant HA-RXFP3 Δ1–33.
This construct removes the D5, D19, E23, D30, and E33 residues
while keeping the highly conserved potential N-glycosylation sites,
which are likely to be essential for receptor cell surface expression
(Figure 2).
EFFECTS OF MUTAGENESIS ON BINDING
Conserved E/D residues identiﬁed from sequence alignments were
mutated to Ala in human RXFP3 (highlighted in Figures 1 and
2) to test the effect of loss of amino acid side chain on recep-
tor binding using the Eu-labeled RXFP3 agonist H3/I5. Receptor
mutants were tested in parallel for their cell surface expression
and ﬁnal speciﬁc binding data was expressed as a ratio of bind-
ing/cell surface expression (Figure 3). Due to their close proximity
D47A/E51A, E55A/D58A, and E141A/D145A were made as com-
bination mutants in the ﬁrst instance to test the effect of the
loss of both side-chains. Importantly it was immediately clear
that the mutation of E141A/D145A resulted in a dramatic loss
of binding with little effect on the cell surface expression of the
mutant receptors. We therefore produced the individual recep-
tor mutants E141A and D145A and demonstrated that both of
these mutations resulted in a dramatic decrease in binding with
no change in cell surface expression. In contrast, the mutants
D47A/E51A demonstrated no loss in binding whereas E55A/D58A
demonstrated a slight increase in binding and were therefore not
followed up with individual mutations. All of the other iden-
tiﬁed D/E residues, E72A, D75A, E77A, E244A, E245A, D253A,
E362A were produced and tested with most showing no change
in binding or cell surface expression. However, the EL2 residues
which are in close proximity E244A and E245A demonstrated
signiﬁcant loses in binding with E245A also showing signiﬁ-
cantly lower cell surface expression. Additionally, E77A showed
a ∼50% loss of binding with no change in cell surface expres-
sion. Interestingly the truncated mutant Δ1–33 demonstrated
a slight increase in binding demonstrating that D5, D19, E23,
D30, and E33 residues are unlikely to be involved in H3 relaxin
binding.
FIGURE 2 | Snake diagram of the extracellular domains of the human
RXFP3 receptor highlighting residues from the N-terminus and
extracellular loops (ELs).The glutamic (E) and aspartic acid (D) residues in
these domains that have been mutated to alanine in this study are highlighted
in purple. The site of truncation to form the N-terminally truncated receptor
HA-RXFP3 Δ1–33 is indicated and potential N-gylcosylation sites are also
highlighted. The putative disulphide bond between C156 in EL1 and C247 in
EL2 is represented with a red dotted line.
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FIGURE 3 | (A) Eu-H3/INSL5 binding to mutant receptors expressed on the
surface of cells. Data are expressed as a ratio of speciﬁc Eu-H3/I5 binding
to the cell surface expression (B) of each construct and are normalized to
HA-RXFP3 binding. (B) Cell surface expression of the various RXFP3
mutant receptors compared to HA-RXFP3. All data are the mean of
triplicate determination from 4 to 8 independent experiments. *p < 0.001
vs HA-RXFP3, #p < 0.01 vs HA-RXFP3.
The speciﬁc binding data clearly identiﬁed E141A and D145A
in EL1 and E244A in EL2 as being involved in H3 relaxin bind-
ing, with possible additional contributions from E77A in the
N-terminus and E245 in EL2. The speciﬁc binding levels of
E141A, D145A, and E244A were too low for further analysis.
However, both E77A and E245A demonstrated enough speciﬁc
binding to enable further analysis using competition binding
assays using H3 relaxin as the competing ligand. They were
therefore compared with wild-type RXFP3, HA-RXFP3 and var-
ious other mutants which demonstrated either no change in
(D75A), or slightly increased (Δ1–33, E55A/D58A), speciﬁc bind-
ing (Figure 4; Table 3). Importantly as can be seen in Figure 4
and in Table 3 there was no difference in the binding afﬁnity
of H3 relaxin to HA-RXFP3 in comparison to wild-type RXFP3
(pIC50 = 7.53 ± 0.06 and 7.89 ± 0.14, respectively). The trunca-
tion of the N-terminus to produce Δ1–33 also had no signiﬁcant
effect on the afﬁnity of H3 relaxin (pIC50= 7.83± 0.08) although
there was a slightly higher speciﬁc binding of Eu-H3/I5. There was
also no signiﬁcant difference in the afﬁnity of H3 relaxin for D75A
(pIC50=7.70±0.16) and although the afﬁnity of E55A/D58Awas
FIGURE 4 | Competition binding data for representative mutant RXFP3
receptors compared to HA-RXFP3. (A)Wild-type RXFP3 and the
N-terminally truncated mutant Δ1–33. (B) N-terminal domain mutants. (C)
Exoloop 2 mutants. Data are presented as pooled % speciﬁc binding of
triplicate determinations from 4 to 9 independent experiments.
slightly higher in line with the higher Eu-H3/I5 binding, this was
not signiﬁcantly different fromHA-RXFP3 (pIC50 = 8.03 ± 0.20,
p > 0.05). Finally both E77A and E245A which demonstrated
an ∼50% decrease in Eu-H3/I5 binding demonstrated slightly
lower H3 relaxin binding afﬁnity but this was not signiﬁcantly
different from HA-RXFP3 (pIC50 = 7.50 ± 0.22 and 7.35 ± 0.09,
respectively, p > 0.05).
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Table 3 | Competition binding results for HA-RXFP3 mutants.
Construct pIC50 n
RXFP3 7.53 ± 0.06 9
HA-RXFP3 7.89 ± 0.14 8
HA-RXFP3 Δ1–33 7.83 ± 0.08 4
HA-RXFP3 E55A/D58A 8.03 ± 0.20 4
HA-RXFP3 D75A 7.70 ± 0.16 4
HA-RXFP3 E77A 7.50 ± 0.22 4
HA-RXFP3 245A 7.35 ± 0.09 4
MODEL OF RELAXIN-3/RXFP3 INTERACTION
To illustrate the nature of H3 relaxin–RXFP3 complex the muta-
tional data on RXFP3 generated in this study and previously
reported structure activity relationships of H3 relaxin were used
to generate a molecular model. As starting structures we used the
NMR solution structure of H3 relaxin (Rosengren et al., 2006) and
the crystal structure of the chemokine receptor CXCR4 in com-
plex with the antagonist CVX15 (Wu et al., 2010). Although the
structure of CXCR4 is in its inactive state this structure represents
a good template for modeling the binding site given it is closely
related toRXFP3 (30% identity and60%similarity) and it is bound
to a peptide ligand creating a more “open” conformation required
for binding of a large ligand like H3 relaxin. The sequences of the
seven transmembrane helices as well as some of the loop regions
could be aligned between receptors without ambiguity, allowing
a homology model of RXFP3 to be built by comparison using
the program package Modeller 9v10 (Sali and Blundell, 1993). H3
relaxin was docked into the receptor during the comparativemod-
eling procedure by utilizing the similarities between key features
of the CVX15 ligand and the activation domain of H3 relaxin, R26
andW27, as well as loose distance restraints bringing the positively
charged key arginine residues of the ligand, R12 and R16, into the
proximity of the key negatively charged residues D145 and E244
of RXFP3.
A representative model of the complex is shown in Figure 5,
which highlights the key features of the proposed binding mode.
The binding surface of the H3 relaxin B-chain helix packing up
against EL1 and EL2, creating a network of electrostatic interac-
tions betweenR16 andD145 aswell as betweenR12 andE244. This
arrangement suggests that the more hydrophobic face of the helix,
which includes I15 and I19 is able to interact with a hydropho-
bic region on EL2. The C-terminus of the H3 relaxin B-chain is
able to be accommodated deep into the transmembrane helical
bundle with R26 directly interacting with the critical E141 at the
top of TM2, consistent with this region being able to induce the
structural rearrangement required for activation. No direct con-
tacts with the ligand are observed, or likely to be possible byminor
rearrangements, for either E77 or E245. Thus the minor effects of
mutations observed for these residues are likely related to minor
destabilization of the fold.
DISCUSSION
Recent physiological evidence has highlighted an important role of
the relaxin-3/RXFP3 signaling system in a number of neurological
FIGURE 5 | Model of the RXFP3-H3 relaxin complex. H3 relaxin is shown
in pink and RXFP3 in gray. All Asp/Glu residues in RXFP3 mutated during
this study are shown in red and labeled with residue numbers. Key Arg and
hydrophobic residues in H3 relaxin involved in the receptor binding are
highlighted in blue and green, respectively, and labeled with residue
numbers. Key features are the electrostatic interactions between the
positively charged R12, R16, and R26 of H3 relaxin and the negatively
charged E244, D145, and E141 of RXFP3, respectively.
signaling processes including feeding, stress responses, arousal,
and cognition (Smith et al., 2011; Ganella et al., 2012b). These
ﬁndings have sparked considerable interest in RXFP3 as a potential
pharmacological target for multiple neurological diseases. How-
ever, the only current agonists or antagonists that are known
to target this receptor are peptides which must be administered
intracerebroventricularly for in vivo studies in rodents (Haugaard-
Kedstrom et al., 2011; Shabanpoor et al., 2012). Although residues
in these peptides have been identiﬁed as critical for activ-
ity, the speciﬁc residues in the receptors that are interacting
with these are unknown. Detailed knowledge of relaxin-3 bind-
ing site in RXFP3 would enable a structure-based drug design
approach to design small molecule agonists and antagonists. We
have therefore used comparative sequence analysis, molecular
modeling and receptor mutagenesis to investigate the bind-
ing site of the native ligand H3 relaxin on the human RXFP3
receptor.
Previous peptide structure function studies have demonstrated
that the H3 relaxin B-chain alone is interacting with the recep-
tor (Liu et al., 2003b; Hossain et al., 2008). Subsequently it has
been demonstrated that residues around the H3 relaxin B-chain
central helix including R8, R12, I15, R16, and F20 are important
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for RXFP3 binding whereas all except R12 are also important for
RXFP4 binding (Kuei et al., 2007). Additionally, the C-terminal
two residues of the B-chain R26 and W27 were demonstrated to
be essential for receptor activation (Kuei et al., 2007; Figure 1B).
The evidence suggests that theH3 relaxin B-chain is binding to the
extracellular domains of the receptor using residues from the cen-
tral helix whereas R26 and W27 may interact within the RXFP3
transmembrane helices to induce the active receptor conforma-
tion (Kuei et al., 2007; Kong et al., 2010). So in this study we have
focused our attention on the binding interactions between the
residues in the central helix of the H3 relaxin B-chain and the
RXFP3 ELs and/or NT domain.
Based on the hypothesis that coevolution of relaxin-3 and
RXFP3 occurred in vertebrates, and in the knowledge that the
key relaxin-3 B-chain residues are conserved across all vertebrate
species (Wilkinson et al., 2005b), we performedmultiple sequence
alignments of all vertebrate RXFP3 sequences to identify highly
conserved residues in the ELs andNTdomain thatmay be involved
in relaxin-3 binding. As H3 relaxin also binds to and activates
human RXFP4 (Liu et al., 2003a) we have also used human RXFP4
in the sequence analysis. We have focused on glutamic (E) and
aspartic acid (D) residues in these regions that may form electro-
static interactions with critical arginine residues in the relaxin-3
B-chain. As R12 has been demonstrated to not be involved in
RXFP4 binding whereas R8 and R16 have (Kuei et al., 2007), it is
likely that some E/D residues are conserved in RXFP4 but some
not. All of the identiﬁed E/D residues are highlighted in Figure 2
which also demonstrates where we have truncated the N-terminus
to residue 34 to produce the mutant HA-RXFP3 Δ1–33. Trun-
cation of the N-terminus is an easy method to exclude residues
as potential interacting sites with the ligand. We only truncated
RXFP3 to residue 34 as there are highly conserved potential N-
glycosylation sites at N36 and N40, which are likely to be essential
for receptor cell surface expression as has been demonstrated
for numerous GPCRs (Lanctot et al., 2005) including the related
RXFP1 receptor (Yan et al., 2008).
Conserved D/E residues in the ELs and NT domain were
mutated to Ala in human RXFP3 to test the effect of loss of amino
acid side chain on receptor binding using the Eu-labeled relaxin-
3 agonist Eu-H3/I5. The speciﬁc binding assays identiﬁed almost
complete loss of binding for residues E141A andD145A inEL1 and
residue E244A in EL2. Additionally, E77A in the NT domain and
E245A in EL2 demonstrated decreased speciﬁc binding although
when analyzed with more detailed competition binding there was
no signiﬁcant difference in H3 relaxin afﬁnity. Importantly, the
E245A mutant also demonstrated lower cell surface expression
indicating that this residue may be important for the EL structure.
None of the other D/Emutations showed any signiﬁcant change in
binding or cell surface expression as was the case with the Δ1–33
truncation highlighting that residues 1–33 and other D/E residues
are not involved in H3 relaxin binding. It is therefore clear that
E141A and D145A in EL1 and residue E244A in EL2 are essential
for H3 relaxin binding.
Based on the mutational data a model was created utilizing
structural information in the form of a solution NMR structure
of the H3 relaxin ligand (Rosengren et al., 2006) and a homol-
ogy model of RXFP3 derived from the crystal structure of CXCR4
(Wu et al., 2010). Although the structure of CXCR4 represents an
antagonist bound inactive form it is a good template for visualiz-
ing the binding site as RXFP3 and CXCR4 are closely related and
both respond to stimulation by protein ligands, rather than small
molecules. For both relaxin-3 and the native ligand of CXRC4,
CXCL12, a similar model of receptor binding and activation has
been proposed, which involves two steps: ﬁrst, an initial recogni-
tion that involves an interaction between the globular part of the
protein ligand and the extracellular loops of the receptor and sec-
ond, an insertion of a ﬂexible arm into the transmembrane helical
bundle to induce a structural change leading to intracellular sig-
naling (Crump et al., 1997). It is interesting to note that in the
case of CXCL12 this “activation arm” is located at the N-terminus
while for relaxin-3 the activation domain is at the C-terminus of
the B-chain.
The model of the RXFP3 receptor reveals that the three acidic
residues identiﬁed as critical for ligand binding, E141, D145,
and E244, are ideally positioned to coordinate three arginines in
relaxin-3. R12 and R16, which are located on the B-chain helical
segment, interact with E244 and D145, respectively. This arrange-
ment allows the more ﬂexible C-terminal tail of H3 relaxin to
insert deeper into the receptor’s binding pocket where R26 can
form a salt-bridge with E141, which is located at the C-terminal
end of TM2. These pairings of electrostatic residues are consis-
tent with the sequence analysis showing that E141 and D145 are
conserved across all RXFP3/4 sequences whereas E244 is only con-
served in RXFP3 sequences, thus E244 is likely to be involved in
the R12 interaction which is relaxin-3/RXFP3-speciﬁc. Although
it is difﬁcult to draw too many conclusions about the exact ori-
entation of the activation domain within the TM bundle without
further mutational data it is interesting to note that in the sug-
gested arrangement W27 forms extensive hydrophobic contacts
with residues at the TM5/TM6 interface, and it is possible that
a coordinated effect resulting from this interaction together with
the R26–E141 salt-bridge induces the rearrangement of the bundle
resulting in activation of the receptor. Furthermore, the nega-
tively charged residue at position 141 is conserved also in CXCR4
(D97). In a CXCR4 crystal structure with a small molecule antag-
onist bound this Asp forms a salt-bridge with the ligand (Wu
et al., 2010), and given it has also been shown to be important for
binding of the native agonist ligand CXCL12 (Brelot et al., 2000),
this ligand interaction point appears to be conserved between the
receptors.
The mutational data also suggested a possible involvement of
E77 and E245 in ligand binding, however, neither is in contact
with relaxin-3 in our model. Competition binding experiments
using H3 relaxin did not show a signiﬁcant drop in binding to
either of these residues thus it seems likely that the reduced speciﬁc
binding of the Eu-H3/I5 tracer may be related structural effects
of these mutations, rather than direct contacts. This suggestion is
consistentwith theE245Aanaloghaving signiﬁcantly lower surface
expression that may be related to misfolding or misprocessing. Of
the remaining residues in H3 relaxin identiﬁed as contributing to
binding I15 and I19 are in close contact with EL2 in our model,
while R8 and F20 do not appear to directly contact the receptor in
the suggested arrangement. It is however, possible that both these
residues could come into contact with the N-terminal domain,
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should it move closer to the ligand. The exact positioning of the
N-terminus is highly ambiguous based on current data, due to low
homology and deﬁned structural features it was in this studymod-
eled as disordered. However, studies on chimeric RXFP3/RXFP4
receptor have suggested that in fact it does contribute, at least to
the INSL5 binding to RXFP4 (Zhu et al., 2008), thus structural
changes that allows such contacts is a possible explanation for this
observation.
In summary, we have in this study provided the ﬁrst informa-
tion about the ligand binding site of the relaxin-3 receptor RXFP3.
We have identiﬁed three negatively charged residues in EL1 and
EL2 that coordinate an interaction with three positively charged
arginines inH3 relaxin. Our data provide a ﬁrstmodel of relaxin-3
interaction with RXFP3, which will inform further interrogation
of the agonist binding site.
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